Erbitux Plus Chemo Improves Lung Cancer Outcomes
byBy Amanda Gardner
HealthDay Reporter
SATURDAY, May 31 (HealthDay News) -- The long-awaited results of a trial of the biologic drug Erbitux on patients with advanced non-small cell lung cancer show it prolonged survival by about five weeks when combined with chemotherapy.
Medical professionals have known the drug improved survival, but the question has been by how much.
